Drugs / TAS-115
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04999761 Background | Jun 2021 → May 2026 overdue | alveolar soft part sarcoma, biliary tract cancer, colorectal cancer, esophageal cancer +4 | Taiho Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAS-115 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04999761 ↗ |
| Known as | Pamufetinib | ChEMBL registry synonym — accepted as the source's own label CHEMBL3764045 ↗ |
| Action | Inhibit | “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL3764045 ↗1“Hepatocyte growth factor receptor inhibitor” CHEMBL3764045 ↗ |
| Modality | Small molecule | — CHEMBL3764045 ↗ |
| Route | Oral | “administered orally” NCT04999761 ↗ |
| Target | KDR | “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL3764045 ↗ |
| Target | MET | “Hepatocyte growth factor receptor inhibitor” CHEMBL3764045 ↗ |